Request Demo

Last update 29 Aug 2026

Oxycodone Hydrochloride

Last update 29 Aug 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Oxycodone hydrochloride (USP), Oxycodone Hydrochloride Hydrate, ATLP-02

+ [32]

Target

Opioid receptors

Action

agonists

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Cancer PainChronic PainPain

Inactive Indication

Acute PainAnalgesiaLow Back Pain+ [1]

Originator Organization

Roxane Laboratories, Inc.

Active Organization

SpecGx LLC

Genus Lifesciences, Inc.

Beijing Wellso Pharmaceutical Co., Ltd.

+ [3]

Inactive Organization

Beijing Mengdi Pharmaceutical Co. Ltd.

Purdue Pharma LP

Bard Pharmaceuticals Ltd.

+ [5]

License Organization

Protega Pharmaceuticals, LLC.

Inspirion Delivery Sciences LLC

Daiichi Sankyo, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (26 Oct 1998),

Pain

Regulation-

Structure/Sequence

Molecular FormulaC18H22ClNO4

InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N

CAS Registry124-90-3

668

Clinical Trials associated with Oxycodone Hydrochloride

NCT05265052

/ Not yet recruitingPhase 2

A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain

This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.

Start Date01 Dec 2026

Sponsor / Collaborator

Aitisi Biotechnology (Shanghai) Co. Ltd.

ChiCTR2600131017

/ Not yet recruitingNot ApplicableIIT

Efficacy and safety of oxycodone for postoperative analgesia in patients undergoing thoracoscopic lung surgery: a prospective, multicenter, randomized controlled trial

Start Date01 Sep 2026

Sponsor / Collaborator-

ChiCTR2600128511

/ Not yet recruitingNot ApplicableIIT

Oxycodone versus Sufentanil for Postoperative Pain and Perioperative Inflammatory Response in Patients Undergoing Thoracoscopic Surgery

Start Date25 Jul 2026

Sponsor / Collaborator

Second Hospital of Shanxi Medical University

100 Clinical Results associated with Oxycodone Hydrochloride

100 Translational Medicine associated with Oxycodone Hydrochloride

100 Patents (Medical) associated with Oxycodone Hydrochloride

3,304

Literatures (Medical) associated with Oxycodone Hydrochloride

01 Aug 2026·NEUROSCIENCE

Sex differences in the effects of chronic stress and oxycodone associative learning on glial markers in rat hippocampus

Article

Author: Gray, Jason D ; Kogan, Joshua ; Kim, Annabelle ; Zhou, Yan ; Warwick, Sydney ; Sommer, Garrett ; Milner, Teresa A ; Gregoire, Lennox ; Hirschkorn, Ma'ayan

Prior studies revealed significant sex differences in hippocampal opioid neuronal networks especially after chronic immobilization stress (CIS) that have important implications for opioid associative learning. Besides neurons, glia play important roles in hippocampal associated learning and can be affected by sex and environmental conditions. Here, we examined the relationship of sex and CIS on microglia (ionized calcium binding adapter molecule, Iba1) and astrocyte (glial fibrillary acidic protein, GFAP) densities in rat hippocampus following conditioned place preference (CPP) to saline (Sal) or oxycodone (Oxy). Although baseline glial densities were few, Sal females compared to Sal males had lower CA3b Iba1 and CA1. Following Oxy CPP, only females had increased Iba1 densities in CA3b and CA2/3a and GFAP densities in CA1, but both sexes had increased GFAP densities in CA3b. Moreover, compared to Sal counterparts, GFAP densities were lower in dentate gyrus (DG) in Oxy females and in CA1 in Oxy males. CIS females and males compared to unstressed counterparts had decreased CA3b Iba1 and GFAP densities and DG GFAP densities, however, these decreases were more extensive in males. Oxy CIS females, which acquired Oxy CPP, primarily had increased Iba1 and GFAP densities in CA1 and CA3 and decreased GFAP densities in DG. In contrast, Oxy CIS males, which did not acquire Oxy CPP, primarily exhibited increases in GFAP densities in the DG. These studies, together with our prior studies, reveal significant sex differences in the hippocampal glial densities, especially after CIS, which have important implications for Oxy associated learning processes.

03 Jul 2026·Expert Opinion On Drug Safety

Drug-induced nasal septum perforation: a disproportionality analysis of the FDA adverse event reporting system database

Article

Author: Xie, Chubo ; Wang, Yuewu ; Qiu, Qianhui ; Liu, Yitong ; Jiang, Zhilin ; Cui, Yi ; Sun, Fang ; Zhou, Suizi ; Wang, Keshuang

BACKGROUND:

Nasal septum perforation represents a significant clinical concern, with limited investigations into the role of medications in its etiology. This study utilizes the FDA Adverse Event Reporting System (FAERS) database to identify the drugs associated with nasal septum perforation and assess their risk.

RESEARCH DESIGN AND METHODS:

This retrospective pharmacovigilance study analyzed drug-induced nasal septum perforation data from January 2004 to December 2023. Disproportionality analysis using reporting odds ratio (ROR) assessed drug associations with nasal septum perforation.

RESULTS:

For 552 identified cases, the most commonly reported drugs were bevacizumab (n = 56), fluticasone propionate (n = 50), methotrexate (n = 34), hydrocodone and acetaminophen (n = 22), and paclitaxel (n = 17). Twenty-six drugs showed positive risk signals, with the top five being azelastine hydrochloride and fluticasone propionate (ROR = 173.82), beclomethasone dipropionate (ROR = 90.91), oxymetazoline (ROR = 53.77), desmopressin (ROR = 51.43), and leucovorin (ROR = 42.83). Intriguingly, 18 of these drugs did not list nasal septum perforation as a known side effect.

CONCLUSION:

This study provides a comprehensive overview of drug-induced nasal septum perforation from a pharmacovigilance perspective, highlighting the need for further research to clarify these associations and update drug safety information to reduce patient risk.

01 Jul 2026·MOLECULAR IMMUNOLOGY

HSP47 inhibitor Col003 attenuates thromboinflammation after cerebral ischemia-reperfusion by suppressing GPVI-mediated CD84 shedding in platelets

Article

Author: Long, Rujin ; Liang, Tingting ; Huang, Haiping ; Li, Haoying ; Liu, Jingli ; Deng, Mengyu ; Xie, Yuliang ; Li, Ruying ; Li, Jinpin ; Yang, Jilan ; Xie, Xiaoyun ; Xie, Zhuoxi ; Zhou, Kejian

BACKGROUND:

Thromboinflammation is a major factor exacerbating neurological damage after reperfusion in ischemic stroke, with platelet collagen receptor glycoprotein VI (GPVI) activation-induced CD84 shedding and its mediated CD4 + T cell migration playing a key role. Our previous work demonstrated that the HSP47 inhibitor Col003 suppresses platelet activation by inhibiting GPVI signalling, thereby downregulating platelet-derived reactive oxygen species (ROS) and inflammatory mediators such as P-selectin. However, its potential to modulate thromboinflammatory responses after cerebral ischemia-reperfusion by regulating CD84 shedding downstream of GPVI remains unclear. This study aims to investigate how Col003 mitigates thromboinflammatory responses after cerebral ischemia-reperfusion, potentially offering a novel therapeutic strategy for ischemic stroke.

METHOD:

The middle cerebral artery occlusion (MCAO) model was employed to simulate ischemic stroke in rats. Reperfusion was performed 2 h after ischemia onset. Col003 was administered via tail vein immediately upon reperfusion. A solvent control group received an equivalent volume of DMSO (0.4% final concentration), and a sham-operated group was also established. Cerebral infarction volume was assessed via TTC staining, and neurological deficit severity was evaluated using the Bederson neurological function score. Histopathological changes, cerebral microthrombosis, and neuronal injury were observed through HE staining and Nissl staining. Immunofluorescence staining detected platelet (CD42) and leukocyte (CD45) adhesion in microvessels (CD31) and CD4 + T cell infiltration on the infarct side. Western blot assessed inflammatory factor expression (TNF-α, IL-1β) in the infarct zone and peripheral blood platelet CD84 levels. Enzyme-linked immunosorbent assay (ELISA) measured serum sCD84 levels. Concurrently, in vitro platelet activation was simulated using collagen (a GPVI agonist) to mimic in vivo conditions, with a GPVI inhibitor serving as a parallel control. The study observed that Col003 mitigated platelet CD84 shedding by inhibiting GPVI effects.

RESULTS:

Col003 treatment significantly improved neurological deficits in MCAO rats, reduced infarct volume, decreased cerebral microthrombus formation and CD4 + T cell infiltration, and downregulated TNF-α and IL-1β expression. Col003 markedly decreased serum soluble CD84 (sCD84) levels while increasing platelet CD84 expression, suggesting inhibition of CD84 shedding. In vitro experiments have demonstrated that Col003 produces functional outcomes similar to those of GPVI inhibitors ((S)-S007-1558, HY-144390), significantly reducing collagen-induced CD84 shedding from platelets.

CONCLUSION:

The HSP47 inhibitor Col003 suppresses GPVI-mediated shedding of CD84 from platelets, alleviates platelet-mediated inflammatory responses and cerebral microthrombus formation, and reduces the infiltration of CD4 + T cells and other immune cells in the cerebral infarct region. These results indicate that targeting HSP47 produces functional effects similar to those achieved by inhibiting the GPVI pathway, thereby providing a novel potential target and therapeutic strategy for ischemic stroke.

257

News (Medical) associated with Oxycodone Hydrochloride

05 Aug 2026

·www.globenewswire.com

Adneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea

Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex-U.S. Licensing Transaction Under the Terms of the Agreement, Adneuris Will Receive an Upfront Payment of $35 Million (USD), Including a U.S. Royalty Investment, Along with Substantial Development and Commercial Milestone Payments and Tiered Royalties on Net Sales Starting in the Double Digits Adneuris Anticipates Submitting a New Drug Application (NDA) for Cebranopadol to the U.S. Food and Drug Administration (FDA) Later This Year for the Treatment of Acute Pain MONMOUTH JUNCTION, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Adneuris Therapeutics, a wholly owned subsidiary of Tris Pharma advancing a new kind of pain medicine, today announced that it has entered into an exclusive license agreement with Maruishi Pharmaceutical Co., Ltd. ("Maruishi"), a privately held, perioperative and pain-focused pharmaceutical company based in Osaka, Japan. This agreement grants Maruishi the rights to develop and commercialize cebranopadol, Adneuris' lead investigational therapy, for the treatment of pain in Japan and South Korea. The agreement marks Adneuris' second ex-U.S. licensing transaction, following its agreement for Greater China, and underscores the company's vision for advancing a new era in pain medicine to treat severe pain. Central to that strategy is cebranopadol, a first-in-class dual-NMR (nociceptin/orphanin FQ peptide (NOP) and µ-opioid peptide (MOP) receptors) agonist that has completed Phase 3 clinical development for moderate-to-severe acute pain and Phase 2 for multiple chronic pain indications. Adneuris plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) later this year. Under the terms of the agreement, Maruishi will pay Adneuris an upfront payment of $35 million (USD), including a $10 million U.S. royalty investment. Adneuris is also eligible to receive substantial development and commercial milestone payments, plus tiered royalties on net sales in Japan and South Korea starting in the double digits. Maruishi will hold exclusive rights to develop and commercialize cebranopadol for pain in the licensed territory. “Maruishi's deep expertise in perioperative and pain management, combined with its established commercial infrastructure across Japan, make them an ideal partner to help bring cebranopadol to patients in these important markets across the globe,” said Ketan Mehta, Founder and Chief Executive Officer of Tris Pharma, the parent company of Adneuris Therapeutics. “This partnership builds on the momentum of our most recent ex-U.S. agreement and reflects the growing recognition of cebranopadol's potential to offer a new first-in-class option for patients living with pain.” "We are pleased to expand our long-standing focus on pain management through this collaboration with Adneuris," said Katsuhito Inoue, President and Representative Director, Maruishi Pharmaceutical Co., Ltd. "Cebranopadol's differentiated mechanism and clinical profile suggest the potential to become an important new option for patients living with pain, and we look forward to working with Adneuris to advance its development in Japan and South Korea." Cebranopadol was evaluated in two pivotal Phase 3 trials — ALLEVIATE-1 (following abdominoplasty) and ALLEVIATE-2 (following bunionectomy) — and overall enrolling more than 2,400 participants across its broader clinical programs. In both ALLEVIATE studies, cebranopadol demonstrated a significant reduction in pain compared with placebo over 48 hours, reduced use of opioid rescue medication, and sustained pain control, supporting its potential to deliver efficacy comparable to standard-of-care therapies, with a differentiated safety profile designed to reduce the risk of side effects associated with conventional opioid treatments, such as dependence and misuse. Aurora Partners served as an advisor to Adneuris in connection with the transaction. About Adneuris Therapeutics Adneuris Therapeutics, a wholly owned subsidiary of Tris Pharma, is dedicated to developing new therapies for people living with pain. Guided by a patient-first approach, the company is focused on advancing innovative science with the goal of improving pain management and addressing unmet patient needs. Adneuris is committed to helping shape the future of pain care through research, collaboration, and a focus on delivering meaningful treatment options. For more information, visit https://adneuris.com/. About Tris Pharma, Inc. Tris Pharma, Inc. is a privately held, innovation-driven biopharmaceutical commercial-stage company that is applying drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain, and disorders of the central nervous system into advanced, targeted drug delivery. Tris markets a portfolio of best-in-class ADHD products and is developing a robust pipeline of differentiated near-term drug candidates. For more information, visit www.trispharma.com. About Cebranopadol Cebranopadol is a first-in-class investigational therapy that targets two key receptors, the nociceptin/orphanin FQ peptide (NOP) and µ-opioid peptide (MOP) receptors (a dual-NMR agonist), for the treatment of moderate-to-severe pain, as well as opioid use disorder (OUD). Studied in over 34 clinical trials in more than 2,400 subjects, cebranopadol's profile has been well characterized in pain management studies, demonstrating positive clinical results in acute pain, chronic pain and diabetic neuropathic pain with a favorable safety profile. The FDA granted Fast Track Designation to cebranopadol for chronic low back pain, and if approved, it has the potential to become the first dual-NMR agonist to provide robust pain relief with a reduced risk of dependence, misuse, addiction or overdose than selective MOP agonists such as oxycodone. Cebranopadol's novel mechanism of action also has potential in treating patients with substance use disorders (SUDs). The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded Tris a five-year grant of up to $16.6 million to study cebranopadol's potential to treat OUDs and SUDs. About Maruishi Pharmaceutical Co., Ltd. Founded in 1888 and headquartered in Osaka, Japan, Maruishi Pharmaceutical Co., Ltd. is a privately held specialty pharmaceutical company focused on the perioperative and pain management fields. Maruishi researches, develops, manufactures and markets anesthetics and perioperative drugs, as well as disinfectants, antiseptics and essential drugs, with the goal of improving the quality of life of patients undergoing medical procedures and living with pain. Maruishi has a strong presence in the Japanese market and a history of partnering with innovative biopharmaceutical companies to bring new therapies to patients across Asia. For more information, visit https://www.maruishi-pharm.co.jp/english/. Contact: Cheryl PatnickTris Pharma732-823-4940 Media Contact: Madelin HawtinLifeSci CommunicationsMHawtin@lifescicomms.com

Phase 3License out/inFast TrackClinical Result

04 Aug 2026

·www.biospace.com

PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(News - August 4, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") , is pleased to announce that, further to its news releases dated July 27, 2026, June 12, 2026, May 12, 2026 and April 22, 2026 (the " Prior News Releases "), it has closed a fourth tranche (the " Fourth Tranche ") of its previously announced non-brokered private placement (the " Offering "), which Fourth Tranche consisted of the issuance of 8,600,000 units (each, a " Unit ") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $215,000. The Company closed an initial tranche on May 12, 2026 consisting of the issuance of 13,600,000 Units for gross proceeds of $340,000, a second tranche on June 12, 2026 consisting of the issuance of 9,800,000 Units for gross proceeds of $245,000 and a third tranche on July 27, 2026 consisting of the issuance of 8,000,000 Units for gross proceeds of $200,000. The Company has received aggregate proceeds of $1,000,000 from all tranches. Each Unit is comprised of one (1) common share (each, a " Share ") in the capital of the Company and one-half (1/2) of one Share purchase warrant (each whole warrant, a " Warrant "). Each Warrant entitles the holder thereof to purchase an additional Share (each, a " Warrant Share ") at an exercise price of $0.05 per Warrant Share for a period of two years from the closing of the Fourth Tranche (the " Fourth Tranche Closing "), subject to an acceleration right, whereby the expiry date of the Warrants may be accelerated if the daily closing price of the Shares equals or exceeds $0.08 per Share (the " Acceleration Price ") on the Canadian Securities Exchange (" CSE ") (or such other recognized securities exchange on which the Shares may then trade) for a minimum of ten consecutive trading days, in which event the Company may accelerate the expiry of the Warrants by giving notice via news release and, in such case, all of the then unexercised Warrants will expire on the 30 th day after the date on which the news release is disseminated (the " Acceleration Right "). The Acceleration Price was incorrectly referenced as $0.10 in the Prior News Releases where it should have been referenced as $0.08. The correct Acceleration Price for all tranches is $0.08 per Share. In connection with the Fourth Tranche Closing, the Company paid a cash fee of $17,200 and issued 688,000 finder's warrants (each, a " Finder's Warrant ") to one eligible finder. The Finder's Warrants are exercisable into one additional Share at an exercise price of $0.05 per Share for two years from the Fourth Tranche Closing, subject to the Acceleration Right. The Company intends to use the aggregate gross proceeds of the Fourth Tranche for short loan repayments, audit, accounting and legal fees, patents and further studies and analysis of rodents and tissues and general working capital purposes. All securities issued in relation to the Fourth Tranche are subject to a hold period expiring four months and one day after the Fourth Tranche Closing, in accordance with applicable securities laws. The securities issued under the Offering, including those in the Fourth Tranche, have not been and will not be registered under the United States Securities Act of 1933 , as amended (the " Securities Act "), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About PreveCeutical PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook . On behalf of the Board of Directors of PreveCeutical Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact: Stephen Van Deventer: +1 604 306 9669 Or Investor Relations ir@preveceutical.com Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the use of proceeds of the Offering. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that the proceeds of the Offering may not be used as stated in this news release and those additional risks set out in the Company's public documents filed on SEDAR+ at . Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES To view the source version of this press release, please visit

Clinical Study

21 Jul 2026

·www.drugs.com

Gait Training Can Help Knee Arthritis

TUESDAY, July 21, 2026 — Changing the way you walk could offer relief from knee arthritis on par with common painkillers, clinical trial results show. Gait retraining involves making a small adjustment to the angle of your foot — a minor change that can yield major benefits, researchers wrote in The Lancet Rheumatology . People who underwent this training experienced pain relief akin to that from either over-the-counter or opioid painkillers, researchers found. The gait retraining also led to less deterioration of knee cartilage, slowing the progression of participants’ arthritis, results showed. “Especially for people in their 30s, 40s or 50s, osteoarthritis could mean decades of pain management before they’re recommended for a joint replacement,” lead researcher Scott Uhrlich , director of the Movement Bioengineering Laboratory at the University of Utah, said in a news release. “This intervention could help fill that large treatment gap.” For the new study, researchers randomly assigned 34 people with knee arthritis to undergo gait retraining, and 34 others to take “sham” training that didn’t actually change their natural gait. All participants had mild-to-moderate arthritis in the inside of their knee joint, which tends to bear more weight than the outside, researchers said. This is the most common form of knee arthritis, but the ideal foot angle for reducing load on that part of the knee differs from person to person. “We used a personalized approach to selecting each individual’s new walking pattern, which improved how much individuals could offload their knee and likely contributed to the positive effect on pain and cartilage that we saw,” Uhrlich said. In their first two visits, participants underwent MRI scans and walked on a treadmill while motion-capture cameras recorded their gait. This gave researchers the data they needed to calculate whether turning the patient’s toe inward or outward would reduce load more, as well as the most useful degree of adjustment. The personalized analysis also allowed researchers to screen out participants who wouldn’t benefit from gait training. After this initial analysis, participants returned to the lab for six weekly gait training sessions. Half were provided training intended to help their knees by changing their gait, and the other half were provided placebo training that replicated their natural gait. A year later, researchers reached out to participants to evaluate their knee health . The patients also underwent a second MRI to assess their knee structure. “The reported decrease in pain over the placebo group was somewhere between what you’d expect from an over-the-counter medication, like ibuprofen , and a narcotic, like OxyContin ,” Uhlrich said. “With the MRIs, we also saw slower degradation of a marker of cartilage health in the intervention group, which was quite exciting.” However, this program will need to be streamlined before it can be widely deployed, researchers said. The motion-capture gait assessment is time-consuming and expensive. The team hopes the training eventually could be performed in a physical therapy clinic, with people practicing what they’ve learned while walking around their neighborhood. “We and others have developed technology that could be used to both personalize and deliver this intervention in a clinical setting using mobile sensors, like smartphone video and a ‘smart shoe,’ ” Uhlrich said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Oxycodone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00847	Oxycodone Hydrochloride	N02AA05	DBSALT000277

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	Japan	Shionogi Pharma Co., Ltd.	01 May 2012
Acute Pain	China	Bard Pharmaceuticals Ltd.	21 Jan 2004
Chronic Pain	China	Bard Pharmaceuticals Ltd.	21 Jan 2004
Pain	United States	Roxane Laboratories, Inc.	26 Oct 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 3	United States	Egalet Ltd.	01 Mar 2016
Osteoarthritis, Spine	Phase 3	United States	Purdue Pharma LP	01 Apr 2004
Analgesia	Phase 1	United States	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	Australia	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	Finland	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	New Zealand	Purdue Pharma LP	01 Jul 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04246697 (CTgov)	Phase 4	Analgesia \| Head and Neck Neoplasms	30	Tylenol+Oxycodone+Morphine (Standard of Care A)	qezwhmtmby(gwtjorhfjw) = xnhhiteswi wsjuzdvljr (zqdgvxexaw, 121.4) View more	-	07 Jul 2026
				Tylenol+Oxycodone+toradol+Morphine+Bupivacaine+Gabapentin (Standard of Care B)	qezwhmtmby(gwtjorhfjw) = irqyxxfakc wsjuzdvljr (zqdgvxexaw, 100.0) View more
NCT03958474 (CTgov)	Early Phase 1	Opioid abuse	12	Oxycodone (Oxycodone)	yhvbtyamuh(pqsfycmxdh) = jwldwzixsx ezfxsoidln (nveaanxtww, 15.3) View more	-	02 Jul 2026
				Oxycodone (Withdrawal)	yhvbtyamuh(pqsfycmxdh) = utvaxhpomp ezfxsoidln (nveaanxtww, 16.5) View more
NCT04316559 (CTgov)	Phase 2	Opioid-Related Disorders	5	TRV734+placebo+oxycodone+methadone (Opioid Withdrawal Suppression Interventions)	jrnqodtesl(msbgelihra) = tfydhjzmch fqufohkuic (aiyawkrlom, bmqzbljrew - kgpbpbqaxg) View more	-	02 Jun 2026
				Oxycodone (Oxycodone 30mg)	vflypjywzb(losipzbqsi) = oohxymqxsc tfnlxidzld (xigvzikseu, tzfglhtmzz - unirktcbsl) View more
NCT07223450 (CTgov)	Phase 1	-	8	oxycodone (Group: Oral)	exxoagpdcd(etucpoxwhp) = grjqwfoqjl qentyluklp (radezjpcne, 1954.6) View more	-	06 May 2026
				oxycodone (Group Intranasal)	exxoagpdcd(etucpoxwhp) = aixpkapfle qentyluklp (radezjpcne, 1824.8) View more
NCT06041425 (Pubmed \| J Vasc Interv Radiol)	Phase 4	Pain	40	Oxycodone	lcnxkxkaom(jdpcpheeap) = Adverse event rates were comparable. zfwwsfpura (kuhvlepfyn )	Positive	01 May 2026
				Sufentanil
NCT03574792 (CTgov)	Phase 2	Pain \| Cutaneous Squamous Cell Carcinoma of the Head and Neck	62	Quality-of-Life Assessment+Oxycodone+Methadone+Gabapentin (Arm I (Gabapentin, Methadone, Oxycodone))	fxzyuvlmep(obhqtignhd) = nncbrusgzt mozhctjrnc (htgdrbzgmz, 10) View more	-	16 Apr 2026
				Quality-of-Life Assessment+Oxycodone+Methadone+Venlafaxine+Gabapentin (Arm II (Gabapentin, Methadone, Oxycodone, Venlafaxine))	fxzyuvlmep(obhqtignhd) = nshjdyxipf mozhctjrnc (htgdrbzgmz, 17) View more
NCT05974501 (CTgov)	Phase 4	complications of arthroplasty \| Osteoarthritis, Knee \| Pain, Postoperative	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	jhcqvroeis(flrdngpgse) = vwxwemfdik pphtmjwqae (tmkmeyndhl, ruyihrbuty - vgjjzshnyp) View more	-	12 Feb 2025
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	jhcqvroeis(flrdngpgse) = vcxcidhrbm pphtmjwqae (tmkmeyndhl, tgsoqqrdob - xalkkmqsyk) View more
NCT01458015 (CTgov)	Phase 4	Neuralgia	3	oxycodone+tapentadol (Oxycodone)	esrjcdqgch(kiicdcvntw) = xpaezyecex iniagetvjp (nflnddekgi, gopfdpnhfm - pjlystpstc) View more	-	17 Dec 2024
				oxycodone+tapentadol (Tapentadol)	esrjcdqgch(kiicdcvntw) = twydfxwzyd iniagetvjp (nflnddekgi, rnapzntvaf - brgnulzcgo) View more
NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Oxycodone+Ibuprofen 800 mg (Standard Protocol)	qnzkgkhnku(lhdhdvpjrs) = mszhzkytat vrttbtvfar (htvyzrfoux, nanjuqvvzo - vvgzbhqsnk) View more	-	19 Sep 2024
				Acetaminophen+Oxycodone+Dexamethasone+Ibuprofen 800 mg+Bupivacaine+celebrex+Gabapentin (Enhanced Recovery Protocol)	qnzkgkhnku(lhdhdvpjrs) = jecajiisep vrttbtvfar (htvyzrfoux, ljeugpxong - esccbnmdbf) View more
NCT04791761 (CTgov)	Phase 1/2	Pain, Postoperative	73	Opioid disposal education+Acetaminophen+Oxycodone+Ibuprofen (Opioid Pain Control)	npdgmqdmym(dwoamhhuyf) = ojjmjcztul kalcqbpttq (hvelwrkfhw, zjcjtcfawm - mdlhjgzlxu) View more	-	16 Aug 2024
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	npdgmqdmym(dwoamhhuyf) = xrmrwcwqtk kalcqbpttq (hvelwrkfhw, feszyodojq - gxjfcmjwnw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis